Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Street Assesses AbbVie

This article was originally published in The Pink Sheet Daily

Executive Summary

With a market cap of a Bristol-Myers or Eli Lilly, AbbVie is worth more in early trading than the remaining Abbott. If it can keep growing Humira sales while making its pipeline pay-off, it will be the poster child for slimmed-down and refashioned pharma.


Related Content

Uptick In 4Q 2013 M&A Deal-Making Likely To Continue Into 2014, PwC Report Predicts
AbbVie Sets Out To Win Over Investors In Its First Financial Call
AbbVie CEO Emphasizes Humira Growth Plans, Potential Of HCV Program
Bardoxolone Blow-Up: Reata/Abbott CKD Drug Halted In Phase III
Abbvie: A Glimpse Of What The New Biopharma Will Look Like
Neurocrine Inks $575 Mil. Deal With Abbott To Develop and Sell Gynecologic, Elagolix


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts